Download the program

8:30 – 9:00 RECEPTION

SESSION 1 Chairpersons – Amos Panet, Jonathan Axelrod

9:00 – 9:30
Alessandro Aiuti, San Raffaele Institute for Gene Therapy, Milan, Italy
Gene therapy for primary immunodeficiencies
9:30 – 9:50
Zelig Eshhar,  Weizmann Institute of Science, Rehovot, Israel
The T-body approach: From the mouse cage to the patient’s bed
 9:50 – 10:05
Yosi Gozlan, Weizmann Institute of Science, Rehovot, Israel
"First AID” for T cell gene therapy: TCR affinity maturation by somatic hypermutation

10:05 – 10:25 COFFEE BREAK
10:25 – 10:45
Michael Hayden, Teva Pharmaceutical Industries, Petah Tikva, Israel
Journey from gene identification to first approved gene therapy – Story of LPL
10:45 – 11:00
Nadir Arber, Tel Aviv University, Tel Aviv, Israel
Selective eradication of cancer cells by adenovirus-based delivery of cytotoxic agents: An alternative method for targeting pancreatic cancer
11:00 – 11:15
Chen Ankri, Bar-Ilan University, Ramat Gan, Israel
Human T-cells engineered to express a PD1/28 costimulatory converter display enhanced anti-tumor activity
11:15 – 11:30
Shay Tayeb, Hadassah  Hebrew University Medical Center, Jerusalem, Israel
Newcastle Disease Virus (NDV) – A novel oncolytic agent for cancer treatment
11:30 – 11:50
 Amotz Shemi, Silenseed Ltd, Jerusalem, Israel
A novel RNAi-based treatment for pancreatic cancer (PC): Pre-clinical  & clinical results
11:50 – 12:05
Rafi Gorodetsky, Hadassah  Hebrew University Medical Center, Jerusalem, Israel
Delivery of placental stromal cells by IM injections for mitigation of lethal radiation effects and enhancement of recovery from bone marrow failure

12:05 – 13:05 POSTER SESSION & LIGHT LUNCH

SESSION 2  Chairpersons - Michael Walker, Marcelle Machluf
13:05 – 13:35
Fulvio Mavilio, Genethon, Evry, France
Dangerous liaisons: gene transfer vectors and the human genome
13:35 – 13:50
Hila Barash, Tel Aviv University, Tel Aviv, Israel
Liver to pancreas transdifferentiation occurs in predisposed cells
13:50 – 14:05
Evelyne Zeira, Hadassah Hebrew University Medical Center, Jerusalem, Israel 
Reversing blindness to sight: Efficient and long-term gene delivery to the retina using the femtosecond laser
14:05 – 14:25
Dan Peer, Tel Aviv University, Tel Aviv, Israel
Nanomedicines: directing the immune response?

14:25 – 14:45 COFFEE BREAK
14:45 – 15:05
Eyal Banin, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Phase I gene therapy trial in Israeli patients with Leber Congenital Amaurosis caused by a founder RPE65 mutation: safety and efficacy update with up to three years of follow-up
15:05 – 15:20
Niza Frankel,Tel Aviv University, Tel Aviv, Israel
Derivation of oncolytic mutant HSV-1 vectors with enhanced replication in malignant cells 

15:20 – 15:35
Uri Ben-David, The Hebrew University, Jerusalem, Israel
High-throughput screening identifies small molecules that selectively eliminate human pluripotent stem cells and prevent teratoma formation
15:35 – 15:50
Adi Shruster, Tel Aviv University, Tel-Aviv, Israel
Targeting neurogenesis in the ventral hippocampus with lentiviral Wnt3a gene transfer improves behavioral symptoms in an Alzheimer's disease model